203 related articles for article (PubMed ID: 25006583)
1. Immunogenicity studies of bivalent inactivated virions of EV71/CVA16 formulated with submicron emulsion systems.
Lin CW; Liu CC; Lu TC; Liu SJ; Chow YH; Chong P; Huang MH
Biomed Res Int; 2014; 2014():670506. PubMed ID: 25006583
[TBL] [Abstract][Full Text] [Related]
2. Immunological evaluation and comparison of different EV71 vaccine candidates.
Chou AH; Liu CC; Chang JY; Lien SP; Guo MS; Tasi HP; Hsiao KN; Liu SJ; Sia C; Wu SC; Lee MS; Hsiao CH; Wang JR; Chow YH; Chong P
Clin Dev Immunol; 2012; 2012():831282. PubMed ID: 23008736
[TBL] [Abstract][Full Text] [Related]
3. Structures of Coxsackievirus A16 Capsids with Native Antigenicity: Implications for Particle Expansion, Receptor Binding, and Immunogenicity.
Ren J; Wang X; Zhu L; Hu Z; Gao Q; Yang P; Li X; Wang J; Shen X; Fry EE; Rao Z; Stuart DI
J Virol; 2015 Oct; 89(20):10500-11. PubMed ID: 26269176
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of monovalent and bivalent vaccines against lethal Enterovirus 71 and Coxsackievirus A16 infection in newborn mice.
Sun S; Jiang L; Liang Z; Mao Q; Su W; Zhang H; Li X; Jin J; Xu L; Zhao D; Fan P; An D; Yang P; Lu J; Lv X; Sun B; Xu F; Kong W; Jiang C
Hum Vaccin Immunother; 2014; 10(10):2885-95. PubMed ID: 25483672
[TBL] [Abstract][Full Text] [Related]
5. Production of EV71 vaccine candidates.
Chong P; Hsieh SY; Liu CC; Chou AH; Chang JY; Wu SC; Liu SJ; Chow YH; Su IJ; Klein M
Hum Vaccin Immunother; 2012 Dec; 8(12):1775-83. PubMed ID: 22992566
[TBL] [Abstract][Full Text] [Related]
6. Immunological and biochemical characterization of coxsackie virus A16 viral particles.
Chong P; Guo MS; Lin FH; Hsiao KN; Weng SY; Chou AH; Wang JR; Hsieh SY; Su IJ; Liu CC
PLoS One; 2012; 7(11):e49973. PubMed ID: 23226233
[TBL] [Abstract][Full Text] [Related]
7. A novel inactivated enterovirus 71 vaccine can elicit cross-protective immunity against coxsackievirus A16 in mice.
Yang L; Liu Y; Li S; Zhao H; Lin Q; Yu H; Huang X; Zheng Q; Cheng T; Xia N
Vaccine; 2016 Nov; 34(48):5938-5945. PubMed ID: 27771182
[TBL] [Abstract][Full Text] [Related]
8. Prospect and challenges for the development of multivalent vaccines against hand, foot and mouth diseases.
Liu CC; Chow YH; Chong P; Klein M
Vaccine; 2014 Oct; 32(47):6177-82. PubMed ID: 25218294
[TBL] [Abstract][Full Text] [Related]
9. Crystal Structures of Yeast-Produced Enterovirus 71 and Enterovirus 71/Coxsackievirus A16 Chimeric Virus-Like Particles Provide the Structural Basis for Novel Vaccine Design against Hand-Foot-and-Mouth Disease.
Lyu K; He YL; Li HY; Chen R
J Virol; 2015 Jun; 89(12):6196-208. PubMed ID: 25833050
[TBL] [Abstract][Full Text] [Related]
10. A virus-like particle-based tetravalent vaccine for hand, foot, and mouth disease elicits broad and balanced protective immunity.
Zhang W; Dai W; Zhang C; Zhou Y; Xiong P; Wang S; Ye X; Liu Q; Zhou D; Huang Z
Emerg Microbes Infect; 2018 May; 7(1):94. PubMed ID: 29777102
[TBL] [Abstract][Full Text] [Related]
11. Identification and characterization of a cross-neutralization epitope of Enterovirus 71.
Liu CC; Chou AH; Lien SP; Lin HY; Liu SJ; Chang JY; Guo MS; Chow YH; Yang WS; Chang KH; Sia C; Chong P
Vaccine; 2011 Jun; 29(26):4362-72. PubMed ID: 21501643
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies induced by recombinant virus-like particles of enterovirus 71 genotype C4 inhibit infection at pre- and post-attachment steps.
Ku Z; Ye X; Huang X; Cai Y; Liu Q; Li Y; Su Z; Huang Z
PLoS One; 2013; 8(2):e57601. PubMed ID: 23451250
[TBL] [Abstract][Full Text] [Related]
13. A new EV71 VP3 epitope in norovirus P particle vector displays neutralizing activity and protection in vivo in mice.
Jiang L; Fan R; Sun S; Fan P; Su W; Zhou Y; Gao F; Xu F; Kong W; Jiang C
Vaccine; 2015 Nov; 33(48):6596-603. PubMed ID: 26529072
[TBL] [Abstract][Full Text] [Related]
14. Immunological and biochemical characterizations of coxsackievirus A6 and A10 viral particles.
Liu CC; Guo MS; Wu SR; Lin HY; Yang YT; Liu WC; Chow YH; Shieh DB; Wang JR; Chong P
Antiviral Res; 2016 May; 129():58-66. PubMed ID: 26899790
[TBL] [Abstract][Full Text] [Related]
15. Formulation and immunological evaluation of a trivalent vaccine comprising emulsified submicron particles and inactivated virions of H5N1/EV71/JEV.
Lin CW; Chang CY; Chen WL; Lin SC; Liao CC; Chang JY; Liu CC; Hu AY; Lu TC; Chou AH; Wu SC; Chong P; Huang MH
Hum Vaccin Immunother; 2013 Nov; 9(11):2378-85. PubMed ID: 23838466
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus core particles containing multiple epitopes confer protection against enterovirus 71 and coxsackievirus A16 infection in mice.
Huo C; Yang J; Lei L; Qiao L; Xin J; Pan Z
Vaccine; 2017 Dec; 35(52):7322-7330. PubMed ID: 29129453
[TBL] [Abstract][Full Text] [Related]
17. Formalin-inactivated EV71 vaccine candidate induced cross-neutralizing antibody against subgenotypes B1, B4, B5 and C4A in adult volunteers.
Chou AH; Liu CC; Chang JY; Jiang R; Hsieh YC; Tsao A; Wu CL; Huang JL; Fung CP; Hsieh SM; Wang YF; Wang JR; Hu MH; Chiang JR; Su IJ; Chong PC
PLoS One; 2013; 8(11):e79783. PubMed ID: 24278177
[TBL] [Abstract][Full Text] [Related]
18. Poorly neutralizing polyclonal antibody in vitro against coxsackievirus A16 circulating strains can prevent a lethal challenge in vivo.
Yao X; Mao Q; Li Y; Hao C; Bian L; Chen P; Gao F; Wu X; Lu W; Gao Q; Li X; Liang Z
Hum Vaccin Immunother; 2018 May; 14(5):1275-1282. PubMed ID: 29337652
[TBL] [Abstract][Full Text] [Related]
19. Protection against enterovirus 71 with neutralizing epitope incorporation within adenovirus type 3 hexon.
Tian X; Su X; Li X; Li H; Li T; Zhou Z; Zhong T; Zhou R
PLoS One; 2012; 7(7):e41381. PubMed ID: 22848478
[TBL] [Abstract][Full Text] [Related]
20. Characterizing Enterovirus 71 and Coxsackievirus A16 virus-like particles production in insect cells.
Somasundaram B; Chang C; Fan YY; Lim PY; Cardosa J; Lua L
Methods; 2016 Feb; 95():38-45. PubMed ID: 26410190
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
